Circulatory System sepsis syndromes
Conditions
Interventions
Ivabradine 5 mg twice daily via an enteral route
Ivabradine 7.5 mg twice daily via an enteral route
placebo twice daily via an enteral route
Sponsors
anesthesia and ICU departement , faculty of medicine, Cairo univ
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -severe sepsis, septic shock or Multiple organ dysfunction syndrome -Sinus rhythm with heart rate ¿ 90bpm
Exclusion criteria
Exclusion criteria: refusal by the patient or the responsible guardian ¿ Patients younger than 18 years of age ¿ Hypersensitivity to the active substance or any of the excipients ¿ Pregnancy, lactation ¿ Patients with a history of pre-existing chronic renal failure with a glomerular filtration rate <30ml/min ¿ Patients with malignant hyperthermia or burn patients ¿ Patients with acute rejection after organ transplantation ¿ Patients who have participated or participate in other studies within the last 3 months ¿ Other types of shock than septic or cardiogenic shock ¿ Patients with severe valvular heart disease ¿ Severe hepatic insufficiency ¿ Sick sinus syndrome ¿ pacemaker-dependency ¿ 3rd degree AV block ¿ Use of potent cytochrome P450 3A4 inhibitors such as antifungals of the azole -type (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reduction in base line heart rate, | — |
Countries
Egypt
Contacts
Public Contactmohamed hashim
leccturer
Outcome results
None listed